TICKERNOMICS Sign up
Last Update: 2023-12-23 06:04:47
NovaBay Pharmaceuticals Inc. ( NBY ) https://novabay.com
0.23USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-83.80%
NBY
SPY
30.72%
-99.02%
NBY
SPY
112.82%
-99.29%
NBY
SPY
201.04%
-99.98%
NBY
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.08
-0.66
1.19
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.07
0.07
0.15
-463.23
0.00
0.48
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-34.29
56.47
-9.36
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
11.2292
-29.14
-32.57
1.78
Other Earnings and Cash Flow Stats:
NovaBay Pharmaceuticals Inc. ( NBY ) Net Income TTM ($MM) is -17.49
NovaBay Pharmaceuticals Inc. ( NBY ) Operating Income TTM ($MM) is -0.58
NovaBay Pharmaceuticals Inc. ( NBY ) Owners' Earnings Annual ($MM) is -6.79
NovaBay Pharmaceuticals Inc. ( NBY ) Current Price to Owners' Earnings ratio is -0.46
NovaBay Pharmaceuticals Inc. ( NBY ) EBITDA TTM ($MM) is -0.49
NovaBay Pharmaceuticals Inc. ( NBY ) EBITDA Margin is -9.36%
Capital Allocation:
NovaBay Pharmaceuticals Inc. ( NBY ) has paid 0.00 dividends per share and bought back -3.088202 million shares in the past 12 months
NovaBay Pharmaceuticals Inc. ( NBY ) has reduced its debt by 0.429 million USD in the last 12 months
Capital Structure:
NovaBay Pharmaceuticals Inc. ( NBY ) Interest-bearing Debt ($MM) as of last quarter is 1
NovaBay Pharmaceuticals Inc. ( NBY ) Annual Working Capital Investments ($MM) are -1
NovaBay Pharmaceuticals Inc. ( NBY ) Book Value ($MM) as of last quarter is 7
NovaBay Pharmaceuticals Inc. ( NBY ) Debt/Capital as of last quarter is 24%
Other Balance Sheet Stats:
NovaBay Pharmaceuticals Inc. ( NBY ) has 3 million in cash on hand as of last quarter
NovaBay Pharmaceuticals Inc. ( NBY ) has 4 million of liabilities due within 12 months, and long term debt 1 as of last quarter
NovaBay Pharmaceuticals Inc. ( NBY ) has 4 common shares outstanding as of last quarter
NovaBay Pharmaceuticals Inc. ( NBY ) has 0 million USD of preferred stock value
Academic Scores:
NovaBay Pharmaceuticals Inc. ( NBY ) Altman Z-Score is -16.84 as of last quarter
NovaBay Pharmaceuticals Inc. ( NBY ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
NovaBay Pharmaceuticals Inc. ( NBY ) largest shareholder is owning shares at 0.00 ($MM) value
Hall Justin(CEO, GC and Director) Bought 69767 shares of NovaBay Pharmaceuticals Inc. ( NBY ) for the amount of $29999.80 on 2021-12-06
6.50% of NovaBay Pharmaceuticals Inc. ( NBY ) is held by insiders, and 3.81% is held by institutions
NovaBay Pharmaceuticals Inc. ( NBY ) went public on 2007-10-26
Other NovaBay Pharmaceuticals Inc. ( NBY ) financial metrics:
FCF:-5.00
Unlevered Free Cash Flow:0.81
EPS:-1.50
Operating Margin:-34.29
Gross Profit Margin:56.47
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-99.87
Beta:1.78
Buffet's Owners Earnings:-6.79
Price to Owner's Earnings:-0.46
About NovaBay Pharmaceuticals Inc. ( NBY ) :
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty retailers, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.